We are on the verge of radically changing how autoimmune diabetes should be treated. The antigen-specific immunotherapy Diamyd^® targets individuals who carry a specific gene type found in up to 40% of all people who suffer from or are at risk of autoimmune diabetes, a textbook example of precision medicine. This is a great discovery and a paradigm shift in the field.